title: Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line             is associated with cancer stem cell-like phenotype.
abstract: Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal malignancies             in the world, often diagnosed at an advanced stage, resistant to conventional             chemotherapy and having high invasive and metastatic potential. The mechanism             of drug resistance of PDA is still not clear. In the present study, we established             two novel pancreatic cancer cell lines PAXC-002 and PAXC-003 from human primary             xenograft models. The cell lines were characterized by morphology, karyotype,             pancreatic cancer marker and short tandem repeat (STR) analysis, and growth kinetics             and tumorigenicity. The in vitro anti-proliferation test revealed that PAXC-002             cell was intrinsically resistant to the standard of care chemotherapy-gemcitabine,             compared with that of PAXC-003 and other widely used pancreatic cancer cell lines.             Interestingly, the gemcitabine resistant PAXC-002 cell line was more potent in             forming colonies in 3-Dimensional matrigel culture conditions and had a higher             percentage of CD133 positive cells, which is recognized as a cancer stem cell             marker, compared to the gemcitabine-sensitive PAXC-003 cell line. In this study,             we present two novel pancreatic cancer cell lines which could be used for gemcitabine             resistance investigation, mechanism identification of pancreatic cancer and anticancer             drug screening. The preliminary data indicate that the drug resistance of pancreatic             carcinoma cells is associated with a cancer stem cell-like phenotype.
authors.affiliation: National Nanjing Center for Drug Screening, China Pharmaceutical University, Jiangsu, People's Republic of China.
authors.forename: Gang
authors.initials: G
authors.lastname: Hu
authors.forename: Fu
authors.initials: F
authors.lastname: Li
authors.forename: Kedong
authors.initials: K
authors.lastname: Ouyang
authors.forename: Fubo
authors.initials: F
authors.lastname: Xie
authors.forename: Xuzhen
authors.initials: X
authors.lastname: Tang
authors.forename: Ke
authors.initials: K
authors.lastname: Wang
authors.forename: Sufang
authors.initials: S
authors.lastname: Han
authors.forename: Zhenzhou
authors.initials: Z
authors.lastname: Jiang
authors.forename: Minghua
authors.initials: M
authors.lastname: Zhu
authors.forename: Danyi
authors.initials: D
authors.lastname: Wen
authors.forename: Xiaoran
authors.initials: X
authors.lastname: Qin
authors.forename: Luyong
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000378:metabolism; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D059785:Karyotype; D051379:Mice; D016513:Mice, SCID; D018895:Microsatellite Repeats; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D014183:Transplantation, Heterologous; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D000093542:Gemcitabine